 A promising novel therapeutic immunosuppressive option in the treatment of renal recipients with a profound effect on the fibrosis reaction is the clinical application of mesenchymal stromal cells MSCs. Allogeneic MSCs offer the advantage of availability for clinical use without the delay required for expansion. 